Requiring drug manufacturers to provide pricing under the federal 340B drug pricing program to pharmacies that enter into contractual agreements with entities covered under the 340B program and prohibiting pharmacy benefits managers from denying patients the freedom to use the pharmacy and healthcare provider of such patient's choice.
Impact
The implementation of SB236 is anticipated to enhance access to pharmaceuticals by preventing discrimination against community pharmacies that participate in the 340B program. It obligates pharmacies to inform patients they are not required to use mail-order services, thus promoting local pharmacies. The bill seeks to eliminate practices that undermine the intended benefits of the 340B program, which aims to provide discounted medication to underserved populations. As a result, the act could significantly improve patient access to necessary medications and support the financial stability of community pharmacies.
Summary
Senate Bill 236, known as the 340B Drug Pricing Nondiscrimination Act, is designed to regulate the interactions between pharmacy benefits managers (PBMs) and pharmacies participating in the federal 340B drug pricing program. The bill mandates that drug manufacturers provide 340B pricing to pharmacies that have contractual agreements with covered entities. It also prohibits PBMs from discriminating against patients or pharmacies based on their participation in the 340B program, ensuring that patients have the freedom to use any pharmacy or healthcare provider they choose without additional restrictions or penalties.
Contention
Opponents of the bill may express concerns regarding the burden that increased regulations might place on PBMs and pharmaceutical manufacturers. Some industry stakeholders could argue that the legislation may lead to increased prices or reduced availability of certain drugs due to formalized requirements imposed on pharmaceutical companies. Proponents, however, assert that safeguarding the integrity of the 340B program is essential for ensuring equitable access to medication for vulnerable populations. The discussions around SB236 reflect broader tensions within the healthcare sector regarding cost, access, and the role of market forces in drug pricing.
Requiring certain 340B entities to report annually to the Kansas department of insurance on certain costs, savings and payments made under the federal 340B drug pricing program.
Pharmacies; prohibit drug manufacturer and wholesalers from preventing a licensed pharmacy from acquiring drugs from entities that participate in a particular federal drug discount program
Health: pharmaceuticals; drug manufacturers from engaging in certain conduct with pharmacies participating with a 340B program; prohibit. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 17757c. TIE BAR WITH: SB 95'25
Health: pharmaceuticals; reporting certain information and regulating certain conduct related to drugs and the federal 340B program; provide for. Creates new act.